Between 1985 and 1996, 51 patients with relapsed or refractory small cleaved cell lymphoma (SCCL) received high-dose chemotherapy ؎ TBI in conjunction with autologous (ABMT) (36 patients) or allogeneic transplantation (15 patients). Patients were eligible for ABMT if the bone marrow biopsy done prior to the planned transplant did not reveal microscopic involvement with SCCL. Patients receiving ABMT had a median age of 48 years, had received a median of 2.5 chemotherapy regimens prior to transplantation, and were transplanted a median of 35.5 months from diagnosis. Among patients receiving ABMT, 5 year actuarial survival was 56 ؎ 11%. Median survival was 126؉ months, and median survival from diagnosis was 191 months. Univariate and multivariate analysis identified sensitive disease as the best predictor of a favorable response. Five-year actuarial survival was 66 ؎ 12% for patients with sensitive disease at the time of transplant as compared to 29 ؎ 17% for patients with resistant disease, P = 0.015. Median survival in patients with sensitive disease at the time of ABMT was 126؉ months. By univariate analysis, survival was significantly better for patients receiving ABMT as compared to patients receiving allogeneic transplants. Median survival following allogeneic transplantation was 5 months; 5 year actuarial survival was 15 ؎ 13%. In a multivariate analysis, which considered autologous vs allogeneic transplantation, sensitive vs resistant disease, Ͻ3 vs у3 prior treatments, and prior bone marrow involvement, allogeneic transplantation was significantly associated with poor survival. Treatment-related mortality occurred in eight of 15 patients receiving allogeneic transplantation and limited the effectiveness of this therapy. High-dose therapy in conjunction with ABMT is effective therapy for patients with SCCL whose disease is sensitive to chemotherapy and whose marrows are microscopically free of disease. Because of possible selection bias, it has not been proven that this approach increases survival in these patients. Treatment-related
High-dose cytotoxic therapy in conjunction with either autologous bone marrow transplantation (ABMT) or peripheral blood stem cell transplantation (PBSCT) has become established salvage therapy for patients with intermediate-and high-grade non-Hodgkin's lymphomas (NHL) in relapse after primary therapy. [1] [2] [3] [4] However, the value of such therapy in patients with low-grade lymphoma is less well established. 5 Issues such as the optimal timing of therapy, [5] [6] [7] the value of purging, [7] [8] [9] and the relative merit of autologous stem cells vs allogeneic stem cells 10 remain unresolved. Since some patients with low-grade NHL may experience prolonged survival, even with limited initial therapy such as 'watchful waiting', it is difficult to establish that high-dose therapy has an impact on the survival of patients with low-grade NHL. 5, 7 Resolution of these issues is complicated by the fact that only limited data are available. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Additionally, many studies of high-dose therapy and transplantation in low-grade NHL have included cases of mixed cell follicular NHL, 5 ,11 a disorder which may not be a classical low-grade lymphoma. [15] [16] [17] To clarify the role of high-dose therapy in conjunction with stem cell transplantation, this report summarizes our results using autologous or allogeneic bone marrow or stem cell transplantation in patients with follicular small cleaved cell lymphoma (SCCL).
Patients and methods

Patients and eligibility
Records of all patients who received high-dose therapy in conjunction with autologous or matched related allogeneic stem cell transplantation at Vanderbilt University Medical Center or the affiliated Nashville Veteran's Affairs Hospital between August 1985 and December 1996 were reviewed. During this period, 187 patients with non-Hodgkin's lymphoma received autologous transplants and 46 patients with non-Hodgkin's lymphoma received allogeneic transplants. Patients were included in this study if the most recent pathological material prior to transplantation was interpreted as SCCL. Patients with SCCL lymphoma that had transformed to intermediate-grade lymphoma were not included in this analysis nor were patients whose pathological material showed both SCCL and intermediate-grade NHL. Two patients with SCCL who received an allogeneic transplant from either a 5/6 matched related donor or a matched unrelated donor were excluded from this analysis.
Patients with SCCL were eligible for transplantation if they had primary refractory disease or had relapsed following initial standard chemotherapy. Patients with SCCL older than 60 years were generally not considered for autologous transplantation. Since patients were referred to our institution after receiving different amounts of chemotherapy, there was considerable variability with respect to the number of courses of chemotherapy received prior to transplantation and the interval between diagnosis and transplantation. Patients were eligible for autologous bone marrow transplantation if the bone marrow biopsy done immediately prior to the planned transplant did not reveal microscopic involvement with SCCL. Patients with prior bone marrow involvement with SCCL were eligible for autologous transplantation as were patients whose bone marrow specimens were positive only by bcl-2 analysis. During the latter period of this study, peripheral blood stem cells were used as a source of hematopoietic progenitors. These patients are included in this analysis. Five patients whose marrow involvement was detectable only by bcl-2 analysis received autologous bone marrow (three patients) or peripheral blood stem cells (two patients) which had been purged with etoposide and methylprednisolone; 18 these patients were included in the analysis.
To be eligible for transplantation, patients were required to have normal or nearly normal function of kidneys (serum creatinine Ͻ1.5 mg/dl), liver (serum bilirubin Ͻ2.0 mg/dl), lungs (corrected carbon monoxide diffusion capacity Ͼ50% of predicted value) and heart (left ventricular ejection fraction Ͼ50%). All patients were antibody seronegative for HIV.
Patients not eligible for autologous transplantation because of bone marrow involvement at the time of transplant evaluation were evaluated for allogeneic bone marrow transplantation, as were patients who had resistant disease, or multiple brief responses to therapy. Patients older than 50 years were generally not considered for allogeneic transplantation. Patients with recurrent or progressive disease generally received two cycles of DHAP 19 or ESHAP 20 while awaiting transplantation, and underwent transplantation within 2 months of completing salvage chemotherapy. All patients were treated in accordance with Institutional Review Board approved protocols and gave written informed consent.
Preparative regimens
The standard preparative regimen during the course of this study was Cy-VP-TBI, ie, etoposide 1800 mg/m 2 day Ϫ7, cyclophosphamide 50 mg/kg days Ϫ6, Ϫ5 and Ϫ4, and total body irradiation, 5 or 6 fractions of 200 cGy each, delivered on days Ϫ3, Ϫ2 and Ϫ1. Patients who had received extensive prior radiotherapy or who could not receive total body irradiation received CBV, ie, etoposide 2400 mg/m 2 day Ϫ7, cyclophosphamide 1800 mg/m 2 days Ϫ6, Ϫ5, Ϫ4, Ϫ3, and BCNU 400 mg/m 2 day Ϫ2. The first patient in the series received cyclophosphamide and total body irradiation.
Supportive care including graft-versus-host disease (GVHD) prophylaxis
All patients were treated in high efficiency particulate air filtered rooms. Platelet transfusions were routinely administered to keep the platelet count above 20 ϫ 10 9 /l. Red cell transfusions were administered to maintain the hematocrit above 25%. Use of growth factors post-transplant was not uniform as G-CSF and GM-CSF were not commercially available at the start of the study. In general, most recipients of ABMT received G-CSF, 5 g/kg/day (20 patients), or, less frequently, GM-CSF, 250 g/m 2 /day (five patients). Recipients of allogeneic transplants generally did not receive growth factors. However, four patients received G-CSF and one received GM-CSF. Prophylactic acyclovir, fluconazole or low-dose amphotericin B, and antibiotics were routinely administered. Non-absorbable antibiotics were not administered in the course of this study.
Patients receiving allogeneic transplants generally received cyclosporine, 3 mg/kg/day in divided doses, starting day Ϫ1, and methotrexate, 15 mg/m 2 day 1 and 10 mg/m 2 days 3 and 6 (12 patients) as prophylaxis for GVHD. One patient each received cyclosporine alone, cyclosporine with methylprednisolone, and FK-506 with methotrexate. Intravenous immunoglobulin was administered weekly or every other week, until day ϩ100. Starting on day ϩ28, these patients also received either oral trimethoprim/sulfamethoxazole or aerosolized pentamidine as prophylaxis for Pneumocystis carinii pneumonia. Our policy regarding CMV evolved during the course of this study and included, at times, empirical therapy for all patients with grade II or higher GVHD, or pre-emptive therapy for patients showing evidence of CMV antigenemia or viruria.
Response criteria
Staging evaluations were performed prior to transplantation and within 3 months of transplantation. Complete response was defined as disappearance of all clinical and radiologic evidence of disease. Partial response was defined as a Ͼ50% response in measurable disease. Patients whose only evidence of disease following transplantation was minimal radiologic evidence were considered to have a complete response if the questionable disease did not progress over a 6 month period. Since bone marrow biopsies were microscopically negative at the time of autologous transplantation, follow-up did not routinely include bone marrow biopsies in these patients. Follow-up to evaluate diseasefree status included yearly CT scans after the first year.
Statistical considerations
End points included survival (time from transplant to death or latest follow-up), progression-free survival (time from transplant to disease progression or latest follow-up), and survival from time of diagnosis. All intervals were determined as of 1 June 1998. Survival curves were estimated by the Kaplan-Meier method. 21 Univariate analyses were conducted using the log rank method by means of NCSS 6.0 software. Multivariate analyses were conducted using the proportional hazards regression model by means of NCSS 6.0 software. Log rank comparisons between groups employed two-tailed tests. Comparisons of group composition were performed using either t-tests or 2 tests.
Results
Patient characteristics
Characteristics of the 51 patients are shown in Table 1 . Overall, the median age of patients receiving transplants was 46 years (range 29-63 years). All patients had at least stage III disease documented prior to transplantation. Patients had received a median of two chemotherapy regimens prior to transplantation and the median duration from diagnosis to transplant was 35 months (range 6-192 months). Seventy-eight per cent of patients had sensitive disease at transplant, defined as at least a partial response to the regimen administered most recently prior to transplant. The autologous and allogeneic transplant groups did not differ significantly with respect to sex, preparative regimens, number of prior chemotherapy regimens, duration from diagnosis to transplantation, best response prior to chemotherapy, or per cent of patients with sensitive disease. Patients receiving allogeneic transplants were significantly younger and had a significantly higher incidence of bone marrow involvement.
Survival
Among patients receiving autologous transplants, 12 patients have died. The major causes of death were progressive disease (six patients) and infections which occurred in the early post-transplant period (five patients).
One patient developed myelodysplasia (MDS) 47 months following ABMT and died of sepsis. This patient had received CBV rather than total body irradiation but had received both chemotherapy and radiation therapy prior to being evaluated for ABMT. This represents a 2.8% actual risk and a 10% actuarial risk of treatment-related MDS in this population.
The relationship between survival and clinical characteristics among patients receiving autologous transplants is shown in Table 2 . Survival was significantly better among patients receiving transplants while their disease was sensitive to the most recently administered chemotherapy as compared to subjects receiving transplants when their disease was resistant, 66 Ϯ 12% vs 29 Ϯ 17% (P = 0.015) (Figure 1 ). Survival was also significantly better among patients who had received Ͻ3 prior chemotherapy regimens than among patients who had received three or more prior chemotherapy regimens (Figure 2) . Best prior response, duration from diagnosis to transplant, and prior bone marrow involvement were not related to post-transplant survival in patients receiving autologous transplants.
Sensitivity to disease, number of treatment regimens, and time from diagnosis to treatment are inter-related. Therefore, a multivariate analysis of survival was performed in which the independent variables were sensitive vs resistant disease, у3 chemotherapy regimens vs Ͻ3 prior chemotherapy regimens, and interval from diagnosis to treatment у36 months vs Ͻ36 months. In this analysis, sensitive vs resistant disease was significantly associated with survival (P = 0.036). The associations between survival and the number of prior regimens and between survival and the interval from diagnosis to treatment were not significant. A multivariate analysis of survival was also performed in which the independent variables were sensitive vs resistant disease and one prior treatment vs two or more prior treatments. Again, sensitive disease was significantly associated with survival (P = 0.048), while the association between the number of prior regimens and survival was not significant (P = 1.00).
Among patients receiving allogeneic transplants, the major cause of death was toxicity associated with transplantation (eight patients). Three deaths were caused by progressive disease. The eight deaths which were considered complications of allogeneic transplantation included one death from bronchiolitis obliterans -obstructive pneumonia 32 months following transplantation, one death from pulmonary hemorrhage 1 month post transplantation, and six deaths related to GVHD occurring 1-8 months after transplantation. In four of the six patients dying with GVHD, aspergillosis contributed to mortality. Among the recipients of allogeneic transplants, no variables were identified which predicted survival (Table 3) . Survival for the autologous and allogeneic transplant groups is shown in Figure 3 . By univariate analysis, 5-year actuarial survival was significantly better for patients receiving autologous transplants as compared to subjects receiving allogeneic transplants, 56 Ϯ 11% vs 15 Ϯ 13% (P = 0.012). However, these groups are not matched for factors such as marrow involvement and sensitive vs resistant disease. Therefore, a multivariate analysis of survival was performed in which the independent variables were autologous vs allogeneic transplantation, sensitive vs resistant disease, Ͻ3 prior treatments vs у3 prior treatments, and prior marrow involvement vs no prior marrow involvement. In this multivariate analysis of survival, both allogeneic transplantation (P = 0.002) and prior bone marrow involvement (P = 0.034) were significantly associated with a poorer survival. Sensitive vs resistant disease and number of prior regimens were not significantly related to survival in this analysis.
Progression-free survival
Analysis of progression-free survival considers time to disease progression following transplantation. In this analysis, patients who died of transplant-related complications prior to disease progression are censored rather than considered failures.
Among 36 patients treated with AMBT, five patients experienced early treatment-related mortality and one patient died of myelodysplasia while the lymphoma was in remission. Of the remaining cases, eight patients had disease progression a median of 5.5 months following transplantation, six of these eight patients died of progressive 231 Table 3 Survival as related to clinical characteristics among patients receiving allogeneic transplants 
a Log rank test, two-tailed. disease. Among 15 patients treated with allogeneic transplantation, eight died of transplant-associated complications either in the immediate post-transplant period, before the response to transplant could be assessed, or prior to evidence of recurrent or progressive disease. Of the remaining cases, three patients relapsed a median of 7 months following transplantation; all three died of progressive disease. In the patients with advanced disease prior to transplant, relapses occurred at sites of previously documented disease. Actuarial 5-year progression free survival was 71 Ϯ 9% among patients undergoing autologous transplantation and 64 Ϯ 15% among patients receiving allogeneic transplants (P = 0.49) (Figure 4 ). Progression-free survival was significantly better in patients transplanted with sensitive disease as compared to patients transplanted with resistant disease, 77 Ϯ 7% vs 39 Ϯ17% (P = 0.048).
Survival from diagnosis
Median survival from diagnosis was 191 months for patients undergoing ABMT ( Figure 5 ) and 49 months for patients undergoing allogeneic BMT, P = 0.005. Among patients receiving ABMT, median survival from diagnosis was 191 months for patients treated when disease was sensitive and 58 months for patients treated when disease was resistant to the most recently administered therapy, P = 0.012.
Discussion
Among patients with SCCL, aggressive combination chemotherapy may produce better disease-free survival than can be achieved by conservative management. 22 However, there is no proof that aggressive therapy, even including high-dose chemotherapy in conjunction with autologous bone marrow or stem cell transplantation, can improve survival or produce cure. [5] [6] [7] [8] 11, 12, 23 Additionally, the high incidence of bone marrow involvement in SCCL 24, 25 limits the effectiveness of autologous transplantation. Accordingly, the use of purged autologous marrow has been advocated 9, 26 as has the use of allogeneic marrow. 10, 27, 28, 29 Studies of transplantation in low-grade lymphoma suffer from several methodological problems. Some studies include only a minority of patients with low-grade lymphoma among patients with intermediate-or high-grade lymphoma. 13, 14, 30, 31 Studies of low-grade lymphoma may include several histologic types of lymphoma with different natural histories, such as mixed cell lymphoma (large cleaved cell lymphoma 5, 6, 11 and unrecognized cases of mantle cell lymphoma. It is in this context that we report our experience with 51 patients who received autologous or allogeneic transplantation as salvage therapy for documented SCCL.
In this series, ABMT was associated with a 5-year actuarial survival of 56 Ϯ 11%. Median survival from transplantation was estimated as longer than 126 months, and median survival from diagnosis in these patients was 191 months. However, only seven patients were alive beyond 4 years of follow-up, limiting our ability to determine if a plateau in the survival curve was present.
The best predictor of survival among patients receiving ABMT in this series was whether or not the disease was sensitive (partial response or a better response) to the chemotherapy regimen administered immediately prior to ABMT. Patients considered to have sensitive disease had a 5-year actuarial survival of 66 Ϯ 12% after ABMT as compared to a 5-year actuarial survival of only 29 Ϯ 17% among patients with resistant disease (P = 0.015). By univariate analysis, survival was better in patients receiving fewer than three chemotherapy regimens prior to transplantation than in patients who received у3 chemotherapy regimens. However, by multivariate analysis, only sensitive vs resistant disease was significantly associated with survival. Unfortunately, if the optimal time for ABMT is 'before the patient's disease becomes resistant to chemotherapy' this provides limited guidance to clinicians who cannot tell if the disease will be resistant to the next chemotherapy regimen before it is given.
Among patients with SCCL, highly variable figures for median survival, 5 to 10 years, [31] [32] [33] [34] have been reported. Survival from relapse in excess of 5 years has been reported among patients with low-grade lymphoma receiving standard chemotherapy. 35, 36 Our observations regarding survival after transplantation and following diagnosis suggest that performing ABMT when the disease is sensitive to chemotherapy leads to improved survival. However, the confounding factor of selection bias cannot be excluded. Our patients had bone marrows free of lymphoma at the time of autologous transplantation; 58% had never been shown to have bone marrow involvement. This suggests that our patient group might be a favorable subset of SCCL. Additionally, the best results in our series were observed in patients with sensitive disease. Since these patients might have continued to do well in the absence of transplantation, our findings do not prove that ABMT has a favorable impact on survival in SCCL.
In contrast to the excellent results we achieved with autologous transplantation in SCCL, our results with allogeneic transplantation were discouraging. Actuarial survival at 5 years was 15 Ϯ 13% among patients receiving allogeneic transplants. Even among patients receiving allogeneic transplants for sensitive disease, the actuarial 5-year survival was only 24 Ϯ 13%. Results in previously reported series of allogeneic transplantation in low-grade lymphoma are highly variable. 10, 28, 29 In a study including 10 patients with refractory or recurrent low-grade lymphoma, van Biesen and associates 10 reported an actuarial survival of 80% among patients receiving allogeneic transplants. Only two of 10 patients experienced transplant-related mortality. In our series, seven patients (46%) experienced early transplant-related deaths, while an additional patient died of bronciolitis obliterans -organizing pneumonia 32 months after transplantation. Similar transplant-related mortality has been reported by Demirer et al 28 and Dann et al 29 among patients receiving allogeneic transplants as a salvage therapy for Hodgkin's disease, non-Hodgkin's lymphoma, or acute lymphoblastic leukemia. The ultimate value of allogeneic transplantation may, therefore, depend on the ability to decrease transplant-associated mortality. Additionally, further follow-up will be necessary to determine if allogeneic transplantation offers the potential of cure to long-term survivors with SCCL. Among patients surviving allogeneic transplantation for SCCL, 5 year progression-free survival was 64%. However, this was not significantly better than the progression-free survival observed among patients receiving ABMT. The high acute mortality makes it difficult to recommend allogeneic transplantation for patients with SCCL who have a matched related donor but could otherwise be considered for autologous transplantation. Autologous transplantation using purged bone marrow, or purged peripheral blood stem cells, might prove to be the optimal transplant modality in patients with SCCL who cannot be rendered free of marrow involvement. However, further investigation of allogeneic transplantation in this patient population seems warranted as long as patients appreciate that the potential benefits of allogeneic transplantation have not been proven to outweigh the acute risks.
